flair

(redirected from beclomethasone dipropionate)
Also found in: Dictionary, Thesaurus, Medical, Legal, Acronyms, Wikipedia.

flair

Hunting rare
a. the scent left by quarry
b. the sense of smell of a hound

flair

[fler]
(civil engineering)
A gradual widening of the flangeway near the end of a guard line of a track or rail structure.

FLAIR

(language)
An early system on the IBM 650.

[Listed in CACM 2(5):16 (May 1959)].
References in periodicals archive ?
Rachelefsky GS, Chervinsky P, Meltzer EO, et al: An evaluation of the effects of beclomethasone dipropionate aqueous nasal spray [Vancenase AQ (VNS)] on long-term growth in children.
orBec, oral beclomethasone dipropionate (oral BDP), is currently the subject of a confirmatory Phase 3 clinical trial in the treatment of acute GI GVHD.
Beclomethasone dipropionate aerosol 50 mcg / sprinkler, sprinkler package 200-250 dose
Contract awarded for aerosol beclomethasone dipropionate 50 mcg / sprinkler, 200-250 sprinkler dose container
The patent claims beclomethasone dipropionate (BDP) in conjunction with a short duration of high-dose prednisone with a rapid taper for the reduction of mortality associated with GVHD and leukemia.
OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1830857 "Method of Treatment of Graft-versus-Host Disease and Leukemia with Beclomethasone Dipropionate and Prednisone.
The patent claims the use of beclomethasone dipropionate (BDP) to treat irritable bowel syndrome (IBS), a painful gastrointestinal condition that affects approximately 15% of the population in the industrialized world.
orBec[R], oral beclomethasone dipropionate (oral BDP), represents a first-of-its-kind oral, locally acting therapy tailored to treat the gastrointestinal manifestation of GVHD, the organ system where GVHD is most frequently encountered and highly problematic.
These dosage forms include orBec[R], an oral formulation of beclomethasone dipropionate (BDP), a topically active corticosteroid, currently in a confirmatory Phase 3 clinical trial for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), an inflammatory condition arising from hematopoietic stem cell transplantation.
This result is consistent with a 55% reduction in the risk of mortality from a previous Phase II trial of oral beclomethasone dipropionate.